Advertisement

Topics

Hikma, Vectura in dispute with FDA over generic Advair

21:46 EST 8 Nov 2017 | Reuters

LONDON (Reuters) - Hikma and its partner Vectura are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S. market, delaying any eventual approval.

Original Article: Hikma, Vectura in dispute with FDA over generic Advair

NEXT ARTICLE

More From BioPortfolio on "Hikma, Vectura in dispute with FDA over generic Advair"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...